25 results about "Transplant Donors" patented technology

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) in subjects receiving donor cells. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.

The invention belongs to the technical field of tissue engineering, and particularly relates to tissue gel, a preparation method thereof and application of the tissue gel in preparation of drugs for treating adrenal insufficiency. According to the tissue gel, adrenocorticotropin and glucose are dispersed in a hydrogel matrix material, and the mass ratio of the hydrogel matrix material to the adrenocorticotropin to the glucose is (2.5-5): (3 * 10 <-6 >-120 * 10 <-6 >): 50. According to the invention, the unique property of hyaluronic acid is utilized, hyaluronic acid is used as a gel matrix material, the composite tissue gel is formed by adding adrenocorticotropin into hyaluronic acid, and glucose can provide enough energy supply for tissues. The composite tissue gel is used for treating the adrenal gland tissue, activity maintenance before transplantation can be well provided for the adrenal gland tissue, and compared with a traditional transplantation donor treatment method, the survival rate of the transplanted tissue can be increased to a certain degree through treatment of the composite tissue gel.

Method and systems for sorting potential hematopoietic stem cell transplant (HSCT) donors as a donor or non-donor using immunophenotyping of blood samples. The methods and systems can be used to identify a donor for a HSCT or to choose a donor to generate a HSCT blood product that is not likely to result in bad outcomes for a recipient. Also provided herein are methods and systems for training machine learning models that can be used in methods and systems for sorting potential HSCT donors.

The present application describes and claims a new method for identifying and stratifying the risk of developing BK virus nephropathy (hereinafter referred to as "Nx BK‑v") in patients who have undergone a kidney transplant. The method uses an index combination of at least three biomarkers: i) the intensity of the anti-BK‑v memory T lymphocyte (BK‑v specific memory T lymphocyte, hereinafter referred to as "anti-BK‑v LTm") response, ii) the number of incompatibilities occurring in class I and class II HLA alleles between the transplant donor and recipient, and also takes into account iii) the viral load of BK‑v virus in the patient's whole blood. The method of the present invention allows a very accurate assessment of the risk of developing Nx BK‑v during the months after the test in order to optimize immunosuppressive therapy and better preserve the transplanted kidney.

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) or allograft rejection in subjects receiving donor cells. Also disclosed are methods enhancing regulatory T (Treg) cells for use in preventing GVHD. Also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the treated Treg cells. Also disclosed are enhanced Treg cells produced by the disclosed methods that have been engineered to express chimeric antigen receptor (CAR) polypeptide cells.

Systems and methods are described herein for processing electronic medical images to predict one or more donor recipients for a patient. For example, a digital medical image of the patient may be received, wherein the patient is in need of a transplant. A trained machine learning system may be determined. The digital medical image may be provided into the trained machine learning system, the trained machine learning system determining a patient embedding. Using the patient embedding, a subset of donor recipients may be determined. Based on the subset of donor recipients a recommendation of optimal donors may be determined.

The present disclosure relates to the identification of single nucleotide polymorphisms (SNPs) in the Gamma genomic block in the central region of the major histocompatibility complex (MHC) that can be used for matching transplant donors and recipients and determining disease susceptibility.

A computer-implemented method and system for predicting graft rejection are disclosed herein. The method and system can calculate, based on a score, whether graft rejection will occur in a transplant recipient or the probability of prediction of the degree to which graft rejection will occur. The score can be calculated based on transplant recipient data and one or more parameter weights. The transplant recipient data can include cell-free DNA from the transplant donor (dd-cfDNA) and one or more other types of parameters, such as one or more clinical parameters, one or more functional parameters, one or more immunological parameters, one or more transplant recipient characteristics, or one or more transplant characteristics. In some embodiments, the parameters used to calculate the probability of prediction do not include histological parameters.

The present disclosure relates to products and methods for crossmatching transplant donors and recipients. Products and methods provided are based on solid phase supports coated with transplant donor cell membrane fragments. The products and methods are useful in allotransplantation and xenotransplantation.

The present invention discloses a gene editing system for constructing a pig nuclear transplant donor cell for an OCA-1A albinism model and its application. The present invention provides a method for preparing a recombinant cell: the DNA molecule shown in SEQ ID NO: 19 in the chromosomal DNA of a pig cell is replaced with the DNA molecule shown in SEQ ID NO: 18 to obtain a recombinant cell. Implementation method: TYR-gRNA1, whose target sequence binding region is shown in nucleotides 3-22 of SEQ ID NO: 16, TYR-gRNA2, whose target sequence binding region is shown in nucleotides 3-22 of SEQ ID NO: 17, TYR-E1mut-ss126 shown in SEQ ID NO: 18, and NCN protein are co-transfected into pig cells. The present invention has significant application value for the research and development of drugs for OCA-1A albinism and for revealing the pathogenesis of the disease.

The present disclosure relates to the identification of single nucleotide polymorphisms (SNPs) in the Gamma genomic block in the central region of the major histocompatibility complex (MHC) that can be used for matching transplant donors and recipients and determining disease susceptibility.

The embodiment of the application discloses a kind of fecal bacteria transplantation donor-recipient dynamic matching method, device, equipment and medium, in response to donor-recipient matching request, the fecal bacteria transplantation after monitoring data of current preset sampling time of to-be-matched recipient is acquired;Wherein, the fecal bacteria transplantation after monitoring data is determined based on the fecal bacteria group of any one target donor to to-be-matched recipient after completing fecal bacteria transplantation operation, and the target donor is determined based on the genetic feature information, immune feature information and clinical feature information of to-be-matched recipient and multiple candidate donors for adaptability matching;Fecal bacteria transplantation after monitoring data is input into transplantation strategy control model, and at least one of the donor switching strategy and dose adjustment strategy for adjusting to-be-matched recipient in next period is output, overall compatibility evaluation is realized by multi-modal data integration, and treatment scheme is continuously optimized by means of dynamic feedback mechanism, which significantly improves the precision and adaptability of fecal bacteria transplantation treatment.

To provide methods and systems to determine HLA-DPB1 expression.SOLUTION: Disclosed are methods and systems and computer program products for determining DPB1 expression without the need for rs9277534 (3'UTR) sequence data. Such methods are useful in assessing HLA sequencing submitted to or already in donor databases for matches that will reduce the risk of hematopoietic transplant rejection (i.e., graft vs. host disease). The disclosure relates to methods and systems to determine DPB1 expression for HLA typing used to match transplant donors and recipients.SELECTED DRAWING: None

The present disclosure provides methods for the preparation and analysis of a biological sample for maternal transplantation of a receptor wherein the method comprises extracting cell-free DNA from the receptor wherein the cell-free DNA comprises donor-derived cell-free DNA, receptor-derived cell-free DNA, and fetal-derived cell-free DNA, and measuring the amount of cell-free DNA and donor-derived cell-free DNA enables assessment of transplant rejection. The detection of the donor-derived cell-free DNA may be performed based on a locus at which the maternal transplantation receptor and the biological father of the fetus are homozygote and the transplantation donor is heterozygous.

Disclosed are methods for evaluating genetic models that are predictive of autoimmune disease phenotype or status. The methods comprise obtaining genotype data from bone marrow transplant recipients and donors. The autoimmune disease phenotype of the transplant recipient after the transplantation may be used evaluate the effect of genotype on the autoimmune disease. Phenotype comparisons may be made to the transplant donor and / or the transplant recipient prior to the transplantation. The methods may be used to validate genetic models associated with autoimmune disease. The genetic models may be based on one or more genetic variants associated with susceptibility to or protection from an autoimmune disease.

Method and systems for sorting potential hematopoietic stem cell transplant (HSCT) donors as a donor or non-donor using immunophenotyping of blood samples. The methods and systems can be used to identify a donor for a HSCT or to choose a donor to generate a HSCT blood product that is not likely to result in bad outcomes for a recipient. Also provided herein are methods and systems for training machine learning models that can be used in methods and systems for sorting potential HSCT donors.

Disclosed herein are computer-implemented systems, kits, and methods for outputting an amount of contributor-derived nucleic acids in a biological sample, from a pregnant transplant recipient, that comprises nucleic acids from at least three genetically distinct contributors. The amount of contributor-derived nucleic acids may be useful in monitoring the status of a transplant for, e.g., assessing a risk of transplant rejection. In some examples, the at least three genetically distinct contributors may comprise a maternal genomic contributor, a fetal genomic contributor, and a transplant donor genomic contributor. For example, the systems and methods determine an estimated percentage of the contributor-derived nucleic acids and / or estimated percentage of the fetal-derived nucleic acids.

1. Name of the product of this design: Graphical user interface of the enterobacteria transplant donor-recipient matching system for electronic devices. 2. Application of this design product: for electronic equipment. 3. The key design point of this design product lies in the graphical user interface content. 4. The picture or photo that best illustrates the key points of the design: Design 1 interface change state diagram 1. 5. Designate Design 1 as the base design. 6. Purpose of the graphical user interface: to display data information of the enterobacteria transplant donor-recipient matching system of the electronic device. 7. Human-computer interaction method of the graphical user interface: The main view of design 1‑9 is the user login display interface of the enterobacteria transplant donor-recipient matching system. In the main view of Design 1, the user enters the user name and password information and clicks the "Login" button to present the Design 1 interface change state diagram 1, which is used to log in to the enterobacteria transplant donor-recipient matching system. In the design 1 interface change state diagram 1, the user clicks "Donor Sample" at the top of the interface to present the design 1 interface change state diagram 2 for displaying sample information. In the main view of Design 2, the user enters the user name and password information and clicks the "Login" button to present the Design 2 interface change state diagram 1, which is used to log in to the enterobacteria transplant donor-recipient matching system. In the Design 2 interface change state diagram 1, the user clicks "Donor Screening" at the top of the interface to present the Design 2 interface change state diagram 2, which is used to display the sample 16s detection information. In the main view of Design 3, the user enters the user name and password information and clicks the "Login" button to present the Design 3 interface change state diagram 1, which is used to log in to the enterobacteria transplant donor-recipient matching system. In the interface change state diagram 1 of design 3, the user clicks "Donor Information" at the top of the interface to present the interface change state diagram 2 of design 3, which is used to display the qualified donor information. In the main view of Design 4, the user enters the user name and password information and clicks the "Login" button to present the Design 4 interface change state diagram 1, which is used to log in to the enterobacteria transplant donor-recipient matching system. In the design 4 interface change state diagram 1, the user clicks "Donor Sampling" at the top of the interface to present the design 4 interface change state diagram 2 for displaying the sampling information. In the main view of Design 5, the user enters the user name and password information and clicks the "Login" button to present the Design 5 interface change state diagram 1, which is used to log in to the enterobacteria transplant donor-recipient matching system. In the design 5 interface change state diagram 1, the user clicks "Donor Abnormality" at the top of the interface to present the design 5 interface change state diagram 2, which is used to display abnormal situation record information. In the main view of Design 6, the user enters the user name and password information and clicks the "Login" button to present the Design 6 interface change state diagram 1, which is used to log in to the enterobacteria transplant donor-recipient matching system. In the design 6 interface change state diagram 1, the user clicks "finished product information" at the top of the interface to present the design 6 interface change state diagram 2, which is used to display the finished product inventory information. In the main view of Design 7, the user enters the user name and password information and clicks the "Login" button to present the Design 7 interface change state diagram 1, which is used to log in to the enterobacteria transplant donor-recipient matching system. In the Design 7 interface change state diagram 1, the user clicks "Finished Product Matching" at the top of the interface to present the Design 7 interface change state diagram 2, which is used to display the order matching information. In the main view of Design 8, the user enters the user name and password information and clicks the "Login" button to present the Design 8 interface change state diagram 1, which is used to log in to the enterobacteria transplant donor-recipient matching system. In the Design 8 interface change state diagram 1, the user clicks "Finished Product Shipment" at the top of the interface to present the Design 8 interface change state diagram 2, which is used to display the shipment record information. In the main view of Design 9, the user enters the user name and password information and clicks the "Login" button to present the Design 9 interface change state diagram 1, which is used to log in to the enterobacteria transplant donor-recipient matching system. In the design 9 interface change state diagram 1, the user clicks "return visit registration" at the top of the interface to present the design 9 interface change state diagram 2, which is used to display the return visit information.

Disclosed herein are computer-implemented systems, kits, and methods for outputting an amount of contributor-derived nucleic acids in a biological sample, from a transplant recipient who has received at least two transplants, that comprises nucleic acids from at least three genetically distinct contributors. The amount of contributor-derived nucleic acids may be useful in monitoring the status of a transplant for, e.g., assessing a risk of transplant rejection. In some examples, the at least three genetically distinct contributors may comprise a recipient genomic contributor, a first transplant donor genomic contributor, and a second transplant donor genomic contributor. For example, the systems and methods determine an estimated percentage of the contributor-derived nucleic acids and / or estimated percentage of the fetal-derived nucleic acids.

The invention discloses a culture method of a bone tissue organ, and belongs to the technical field of tissue engineering and regenerative medicine. According to the method, a spleen is used as a tissue engineering scaffold platform with complete blood circulation and an original microenvironment, the spleen is shifted to a subcutaneous position which is easy to operate, and a bone tissue donor (including small-particle-size tissue particles or large-volume bone end segments) with development potential is implanted into spleen parenchyma; the functions of blood supply, nutrition delivery and waste removal of the spleen are utilized to realize in-vivo macroscopic development and structural reconstruction of bone tissue organs. According to the method, the natural development process of bone tissues can be simulated, long-term survival and functional maturation of organoids are supported, and an efficient and reliable experimental platform is provided for drug screening, disease modeling, developmental biology research and transplanted donor preparation.

Computer-implemented methods and systems for predicting transplant rejection are disclosed herein. The method and system may calculate a predicted probability of whether a transplant rejection will occur or will occur in the transplant recipient based on the score. The score may be calculated based on transplant recipient data and one or more parameter weights. The transplant recipient data may include free DNA of a transplant donor source (dd-cfDNA) and one or more other types of parameters, such as one or more clinical parameters, one or more functional parameters, one or more immunological parameters, one or more transplant recipient characteristics, or one or more transplant characteristics. In some embodiments, the parameters used to calculate the predicted probability do not include histological parameters.

The present invention discloses a gene editing system and its application in constructing nuclear transplant donor cells for an OCA-1B albinism model pig. The kit provided by the present invention comprises a TYR-gRNA1 having a target sequence binding region such as nucleotides 3-22 in SEQ ID NO: 18, a TYR-gRNA5 having a target sequence binding region such as nucleotides 3-22 in SEQ ID NO: 19, TYR-E4mut-ss153 shown in SEQ ID NO: 20, and an NCN protein. The kit is used for: preparing recombinant cells; preparing an albinism model pig; preparing an albinism cell model or an albinism tissue model or an albinism organ model. The recombinant cells are used as nuclear transplant donor cells for somatic cell cloning to obtain cloned pigs, i.e., albinism model pigs. The present invention has significant application value for the research and development of albinism drugs and for revealing the pathogenesis of the disease.

1. Name of the product of this design: Graphical user interface for screening data of enterobacteria transplant donor-recipient matching system for electronic equipment. 2. Application of this design product: for electronic equipment. 3. The key design point of this design product lies in the graphical user interface. 4. The picture or photo that best illustrates the key points of the design: main view. 5. Purpose of the graphical user interface: to display data information of the enterobacteria transplant donor-recipient matching system screening.

The present invention relates to major histocompatibility complex single nucleotide polymorphisms, and in particular to a nucleotide array for identifying a transplant donor for a recipient, a nucleotide array for matching a transplant donor and a recipient, and a nucleotide array for reducing the likelihood of a transplant recipient developing graft-versus-host disease, the nucleotide array comprising probes specific to one or more single nucleotide polymorphism alleles in the MHCγ block. The present invention also relates to a kit for identifying a transplant donor for a recipient.

Disclosed herein are computer-implemented systems, kits, and methods for determining the amount of nucleic acid derived from a contributor in a biological sample from a transplant recipient, the amount of nucleic acid derived from two or more genetically distinct contributors. The determined amount of nucleic acid derived from a contributor can be useful for monitoring the status of the transplant, for example, to assess the risk of transplant rejection. In some examples, the two or more genetically distinct contributors can include the transplant recipient, the fetus, and the transplant donor. In some examples, the two or more genetically distinct contributors can include the transplant recipient, the first transplant donor, and the second transplant donor. For example, the systems and methods determine an estimated percentage of nucleic acid derived from a contributor and / or an estimated percentage of nucleic acid derived from the fetus.